首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis
Authors:Dorard Coralie  de Thonel Aurélie  Collura Ada  Marisa Laetitia  Svrcek Magali  Lagrange Anaïs  Jego Gaetan  Wanherdrick Kristell  Joly Anne Laure  Buhard Olivier  Gobbo Jessica  Penard-Lacronique Virginie  Zouali Habib  Tubacher Emmanuel  Kirzin Sylvain  Selves Janick  Milano Gérard  Etienne-Grimaldi Marie-Christine  Bengrine-Lefèvre Leila  Louvet Christophe  Tournigand Christophe  Lefèvre Jérémie H  Parc Yann  Tiret Emmanuel  Fléjou Jean-François  Gaub Marie-Pierre  Garrido Carmen  Duval Alex
Institution:Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche Saint-Antoine, Equipe 'Instabilité des Microsatellites et Cancers', Paris, France.
Abstract:Heat shock proteins (HSPs) are necessary for cancer cell survival. We identified a mutant of HSP110 (HSP110ΔE9) in colorectal cancer showing microsatellite instability (MSI CRC), generated from an aberrantly spliced mRNA and lacking the HSP110 substrate-binding domain. This mutant was expressed at variable levels in almost all MSI CRC cell lines and primary tumors tested. HSP110ΔE9 impaired both the normal cellular localization of HSP110 and its interaction with other HSPs, thus abrogating the chaperone activity and antiapoptotic function of HSP110 in a dominant-negative manner. HSP110ΔE9 overexpression caused the sensitization of cells to anticancer agents such as oxaliplatin and 5-fluorouracil, which are routinely prescribed in the adjuvant treatment of people with CRC. The survival and response to chemotherapy of subjects with MSI CRCs was associated with the tumor expression level of HSP110ΔE9. HSP110 may thus constitute a major determinant for both prognosis and treatment response in CRC.
Keywords:
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号